Theorem, Now Chiltern

Chiltern has acquired Theorem, which enables us to further expand our global reach, scientific expertise and therapeutic experience to facilitate your complex trials.

Visit Chiltern.com >


Chiltern Biopharma

In the past decade, Chiltern has conducted more than 1,000 biopharma studies across key therapeutic areas. Theorem’s excellence in biopharmaceutical development will enhance Chiltern’s industry-leading services.

Learn more >


Chiltern Oncology

Theorem’s profound expertise in oncology will strengthen Chiltern’s ability to provide expert-led research services to drive the world’s most complex oncology programs.

Get to Know the Oncology Experts >


Chiltern Source

The perfect fit: With the combined offerings of Chiltern and Theorem, we deliver the world’s most forward-thinking recruitment and functional service provision solutions.

More About Chiltern Source >


Combination Trials

More Experience in Combination Trials Than Any Other Partner

With decades of excellence in biopharmaceuticals, medical devices and in vitro diagnostics, Theorem is the industry authority in patient-centric combination product development and management. From creating robust clinical analytics and data visualization solutions, to honing the therapeutic and cross-functional expertise necessary to conduct intricate trials, our capabilities drive faster, smarter combination product development.

Combination Trial Expertise



EXPERTISE derived from conducting hundreds of trials across all major therapeutic areas for some of the world’s largest pharmaceutical and biotechnology companies.

CAPABILITIES for every phase of development from study startup and feasibility to supply to regulatory submission.

FLEXIBILITY to accommodate trials of every size and to access specific patient populations, including those in new and emerging markets.

Biopharmaceutical Expertise


Medical Device

EXPERTISE in development and regulatory affairs to execute successful medical device trials across all risk classifications and approval pathways globally.

CAPABILITIES in health economics to develop adjunctive reimbursement and safety surveillance programs, and ongoing marketing support.

FLEXIBILITY to develop primary devices as well as implantable devices (e.g., drug-coated or drug-eluting stents) and device-based drug delivery mechanisms.

Medical Device Expertise



EXPERTISE in medical device diagnostics, including in vitro diagnostic (IVD) and in vivo imaging, to develop reagents, instruments and systems.

CAPABILITIES including molecular diagnostics, immunoassay, hematology, flow cytometry and microbiology solutions to streamline entire development programs.

FLEXIBILITY from technologies and strategic alliances to identify sites and investigators that meet technical, statistical and practical requirements for a variety of device and diagnostics trials.

Diagnostics Expertise

theorem thumbs phone

A Moment’s Notice: Theorem THUMBS℠ Alert System

Theorem’s communicative, client-centered approach is not only valuable for you, it’s essential to the work we do. The Theorem THUMBS Alert System will give you the power to express your thoughts in seconds. By staying closely connected, we’re able to foresee needs, tailor solutions and prevent issues. This is the latest innovation proving that, at Theorem, nothing is more important than the work we do for you.


When Analytics Need to Be Your
Advantage, Think Theorem.

Essentially, clinical trials are about one thing: data. How you reach patients and collect, manage, interpret and prepare clinical trial data can be the difference between a successful trial and a costly failure.

Theorem is setting the standard for the way data is being used in clinical research with visual analytics tools and techniques that work in real time to identify meaningful information. When you need data to simplify complex trials, Theorem’s clinical analytics solutions are your advantage.


clinical analytics vid cover

Clinical Analytics

How We Think Differently

Title Here

Description here.


Theorem Updates

Chiltern's Brian Bollwage Authors Articles Featured on Applied Clinical Trials Online

September 18, 2015
“Characteristics of the Successful IND or IDE,” is now available to read on Applied Clinical Trials Online. Brian Boll...
Read more

Chiltern Finalizes Acquisition of Theorem Clinical Research

September 14, 2015
(London, U.K., and Wilmington, N.C.; Sept. 14, 2015) — Chiltern, a leading global contract research organization (CRO), ...
Read more

Theorem’s Prithul Bom and Brian Bollwage to Present at Outsourcing in Clinical Trials (OCT) New England

September 8, 2015
(King of Prussia, PA; Sept. 8, 2015) – Theorem, a leading global contract research organization (CRO) that optimizes trial c...
Read more

Theorem’s Webinar Offers Strategies to Improve Clinical Endpoint Adjudication

September 2, 2015
(King of Prussia, PA; Sept. 2, 2015) — Theorem, a leading global contract research organization (CRO) that optimizes trial c...
Read more

Theorem's Angela Stokes Interviews President of BfArM Germany for Regulatory Rapporteur Journal

August 25, 2015
Angela Stokes, Theorem senior director of regulatory affairs clinical trial group, interviewed Prof. Dr. med Karl Broich, presiden...
Read more

Chiltern Announces Agreement to Acquire Theorem Clinical Research

August 6, 2015
(London, U.K., and Wilmington, N.C.; August 6, 2015) — Chiltern, a leading global contract research organization (CRO), ...
Read more

Theorem to Co-host Webinar on Reviving Trial Enrollment Levels With DAC Patient Recruitment Services

July 30, 2015
(King of Prussia, PA; July 30, 2015) – Theorem, a leading global contract research organization (CRO) that optimizes trial c...
Read more

Theorem’s Jason Monteleone Named a Finalist for Philadelphia Business Journal's CFO of the Year Honor

July 13, 2015
Jason Monteleone, Theorem executive vice president and CFO, was named as one of the finalists for Philadelphia Business Journal...
Read more

The Role of Companion Diagnostics in the Era of Personalized Medicine

June 30, 2015
Brian D. Bollwage, JD, Theorem’s vice president of global regulatory affairs, discusses personalized medicine and companion ...
Read more